256 related articles for article (PubMed ID: 28675319)
1. Nrf2: a potential therapeutic target for naturally occurring anticancer drugs?
Catanzaro E; Calcabrini C; Turrini E; Sestili P; Fimognari C
Expert Opin Ther Targets; 2017 Aug; 21(8):781-793. PubMed ID: 28675319
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs.
Telkoparan-Akillilar P; Suzen S; Saso L
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022969
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1.
Na HK; Surh YJ
Free Radic Biol Med; 2014 Feb; 67():353-65. PubMed ID: 24200599
[TBL] [Abstract][Full Text] [Related]
4. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
5. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy.
Zhu J; Wang H; Chen F; Fu J; Xu Y; Hou Y; Kou HH; Zhai C; Nelson MB; Zhang Q; Andersen ME; Pi J
Free Radic Biol Med; 2016 Oct; 99():544-556. PubMed ID: 27634172
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.
Bai X; Chen Y; Hou X; Huang M; Jin J
Drug Metab Rev; 2016 Nov; 48(4):541-567. PubMed ID: 27320238
[TBL] [Abstract][Full Text] [Related]
7. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.
Hu L; Miao W; Loignon M; Kandouz M; Batist G
Cancer Chemother Pharmacol; 2010 Aug; 66(3):467-74. PubMed ID: 19940992
[TBL] [Abstract][Full Text] [Related]
8. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance.
Jeddi F; Soozangar N; Sadeghi MR; Somi MH; Samadi N
DNA Repair (Amst); 2017 Jun; 54():13-21. PubMed ID: 28415030
[TBL] [Abstract][Full Text] [Related]
9. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds.
Jeong WS; Jun M; Kong AN
Antioxid Redox Signal; 2006; 8(1-2):99-106. PubMed ID: 16487042
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
11. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents.
Giudice A; Arra C; Turco MC
Methods Mol Biol; 2010; 647():37-74. PubMed ID: 20694660
[TBL] [Abstract][Full Text] [Related]
12. Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.
Namani A; Li Y; Wang XJ; Tang X
Biochim Biophys Acta; 2014 Sep; 1843(9):1875-85. PubMed ID: 24851839
[TBL] [Abstract][Full Text] [Related]
13. Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract.
Ohnuma T; Matsumoto T; Itoi A; Kawana A; Nishiyama T; Ogura K; Hiratsuka A
Biochem Biophys Res Commun; 2011 Oct; 413(4):623-9. PubMed ID: 21925486
[TBL] [Abstract][Full Text] [Related]
14. NRF2 addiction in cancer cells.
Kitamura H; Motohashi H
Cancer Sci; 2018 Apr; 109(4):900-911. PubMed ID: 29450944
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity.
Arlt A; Sebens S; Krebs S; Geismann C; Grossmann M; Kruse ML; Schreiber S; Schäfer H
Oncogene; 2013 Oct; 32(40):4825-35. PubMed ID: 23108405
[TBL] [Abstract][Full Text] [Related]
16. Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy.
Malavolta M; Bracci M; Santarelli L; Sayeed MA; Pierpaoli E; Giacconi R; Costarelli L; Piacenza F; Basso A; Cardelli M; Provinciali M
Mediators Inflamm; 2018; 2018():4159013. PubMed ID: 29618945
[TBL] [Abstract][Full Text] [Related]
17. The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance.
Furfaro AL; Traverso N; Domenicotti C; Piras S; Moretta L; Marinari UM; Pronzato MA; Nitti M
Oxid Med Cell Longev; 2016; 2016():1958174. PubMed ID: 26697129
[TBL] [Abstract][Full Text] [Related]
18. Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma.
Tian B; Lu ZN; Guo XL
Chem Biol Interact; 2018 Jan; 280():70-76. PubMed ID: 29223570
[TBL] [Abstract][Full Text] [Related]
19. Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy.
Sharifi-Rad J; Seidel V; Izabela M; Monserrat-Mequida M; Sureda A; Ormazabal V; Zuniga FA; Mangalpady SS; Pezzani R; Ydyrys A; Tussupbekova G; Martorell M; Calina D; Cho WC
Cell Commun Signal; 2023 May; 21(1):89. PubMed ID: 37127651
[TBL] [Abstract][Full Text] [Related]
20. Targeting the NF-E2-related factor 2 pathway: a novel strategy for glioblastoma (review).
Zhu J; Wang H; Fan Y; Lin Y; Zhang L; Ji X; Zhou M
Oncol Rep; 2014 Aug; 32(2):443-50. PubMed ID: 24926991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
